Kelonia Therapeutics develops genetic medicines focused on in vivo gene delivery and cell therapy for cancer and other diseases.
Kelonia Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Kelonia Therapeutics's investors include Venrock, Alta Partners, Horizons Ventures.
Kelonia Therapeutics is headquartered in Boston, United States.
Kelonia Therapeutics develops genetic medicines focused on in vivo gene delivery and cell therapy for cancer and other diseases.
Kelonia Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kelonia Therapeutics — Funding & Investors." VCBacked, April 28, 2022, https://www.vcbacked.co/company/kelonia-therapeutics. Accessed November 11, 2026.
VCBacked. (2022). Kelonia Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/kelonia-therapeutics
{{cite web |title=Kelonia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kelonia-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Kelonia Therapeutics? Request a listing update